Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says

MT Newswires Live03-11

Legend Biotech (LEGN) shares should rebound in 2026 on robust execution of Carvykti to treat multiple myeloma, improving real-world safety and manufacturing expansion, RBC Capital Markets said in a note Tuesday.

Shares have declined due to market sentiment that there are limited catalysts amid rising competition. However, the brokerage said it thinks threats will fail to materialize and that competitive threats are overstated.

RBC said it expects profitability in 2026 as Carvykti expands into earlier lines and community practices due to the rapid adoption driven by "remarkable" single-dose efficacy.

The analysts projected $2.80 billion worth of Carvykti sales in 2026 and $8 billion in peak sales. For Q1, it expects incremental sales growth due to seasonal trends like patients treatment timing preferences and insurance plan transfers in the new calendar years, the analysts said.

Carvykti's franchise profitability is also likely to sustain through 2026, while a strong cash position creates flexibility for internal investments and research and development, according to the note.

RBC reiterated its outperform rating on the stock and adjusted its price target to $62 per share from $66 earlier.

Price: 20.28, Change: +0.72, Percent Change: +3.66

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618295009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618295009","market":"sg","top_or_hot":-1,"title":"Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Legend Biotech (LEGN) shares should rebound in 2026 on robust execution of Carvykti to treat multiple myeloma, improving real-world safety and manufacturing expansion, RBC Capital Markets said in a note Tuesday.</p><p>Shares have declined due to market sentiment that there are limited catalysts amid rising competition. However, the brokerage said it thinks threats will fail to materialize and that competitive threats are overstated.</p><p>RBC said it expects profitability in 2026 as Carvykti expands into earlier lines and community practices due to the rapid adoption driven by \"remarkable\" single-dose efficacy.</p><p>The analysts projected $2.80 billion worth of Carvykti sales in 2026 and $8 billion in peak sales. For Q1, it expects incremental sales growth due to seasonal trends like patients treatment timing preferences and insurance plan transfers in the new calendar years, the analysts said.</p><p>Carvykti's franchise profitability is also likely to sustain through 2026, while a strong cash position creates flexibility for internal investments and research and development, according to the note.</p><p>RBC reiterated its outperform rating on the stock and adjusted its price target to $62 per share from $66 earlier.</p><p>Price: 20.28, Change: +0.72, Percent Change: +3.66</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-11 23:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Legend Biotech (LEGN) shares should rebound in 2026 on robust execution of Carvykti to treat multiple myeloma, improving real-world safety and manufacturing expansion, RBC Capital Markets said in a note Tuesday.</p><p>Shares have declined due to market sentiment that there are limited catalysts amid rising competition. However, the brokerage said it thinks threats will fail to materialize and that competitive threats are overstated.</p><p>RBC said it expects profitability in 2026 as Carvykti expands into earlier lines and community practices due to the rapid adoption driven by \"remarkable\" single-dose efficacy.</p><p>The analysts projected $2.80 billion worth of Carvykti sales in 2026 and $8 billion in peak sales. For Q1, it expects incremental sales growth due to seasonal trends like patients treatment timing preferences and insurance plan transfers in the new calendar years, the analysts said.</p><p>Carvykti's franchise profitability is also likely to sustain through 2026, while a strong cash position creates flexibility for internal investments and research and development, according to the note.</p><p>RBC reiterated its outperform rating on the stock and adjusted its price target to $62 per share from $66 earlier.</p><p>Price: 20.28, Change: +0.72, Percent Change: +3.66</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LEGN","symbol_name":"传奇生物","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618295009","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618295009","pubTimestamp":1773243018,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Legend Biotech  shares should rebound in 2026 on robust execution of Carvykti to treat multiple myeloma, improving real-world safety and manufacturing expansion, RBC Capital Markets said in a note Tuesday.Shares have declined due to market sentiment that there are limited catalysts amid rising competition. However, the brokerage said it thinks threats will fail to materialize and that competitive threats are overstated.RBC said it expects profitability in 2026 as Carvykti expands into earlier lines and community practices due to the rapid adoption driven by \"remarkable\" single-dose efficacy.The analysts projected $2.80 billion worth of Carvykti sales in 2026 and $8 billion in peak sales. For Q1, it expects incremental sales growth due to seasonal trends like patients treatment timing preferences and insurance plan transfers in the new calendar years, the analysts said.Carvykti's franchise profitability is also likely to sustain through 2026, while a strong cash position creates flexibi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LEGN":"传奇生物","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","XBI":"SPDR S&P Biotech ETF","BK4139":"生物科技","BK4581":"高盛持仓"},"translate_title":"加拿大皇家银行表示，由于基本面强劲，传奇生物股价可能会在2026年反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"LEGN":1.5},"content_text":"Legend Biotech (LEGN) shares should rebound in 2026 on robust execution of Carvykti to treat multiple myeloma, improving real-world safety and manufacturing expansion, RBC Capital Markets said in a note Tuesday.Shares have declined due to market sentiment that there are limited catalysts amid rising competition. However, the brokerage said it thinks threats will fail to materialize and that competitive threats are overstated.RBC said it expects profitability in 2026 as Carvykti expands into earlier lines and community practices due to the rapid adoption driven by \"remarkable\" single-dose efficacy.The analysts projected $2.80 billion worth of Carvykti sales in 2026 and $8 billion in peak sales. For Q1, it expects incremental sales growth due to seasonal trends like patients treatment timing preferences and insurance plan transfers in the new calendar years, the analysts said.Carvykti's franchise profitability is also likely to sustain through 2026, while a strong cash position creates flexibility for internal investments and research and development, according to the note.RBC reiterated its outperform rating on the stock and adjusted its price target to $62 per share from $66 earlier.Price: 20.28, Change: +0.72, Percent Change: +3.66","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618295009","isCrawlerRequest":true}